NCT | Title | Condition | Status | Contact |
NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272) | Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Neuroendocrine Tumors, MSI-H Cancer, Cancer With A High Tumor Mutational Burden, Extensive-stage Small-cell Lung Cancer | Recruiting | |
NCT05488314 | A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (NCT05488314) | Carcinoma, Non-Small-Cell Lung | Recruiting | |
NCT04895709 | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (NCT04895709) | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | Recruiting | |
NCT05571839 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors (NCT05571839) | Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma | Recruiting | |
NCT05775289 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (NCT05775289) | Non-small Cell Lung Cancer | Recruiting | |
NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer | Recruiting | djonker@toh.ca |
NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (NCT04449874) | Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors | Recruiting | |
NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (NCT05538130) | Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer | Recruiting | |
NCT05355701 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (NCT05355701) | Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma | Recruiting | |
NCT02468024 | JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer (NCT02468024) | Non-Small Cell Lung Cancer | Recruiting | sgilbert@toh.ca, afazekas@toh.ca |
NCT05714891 | Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer (NCT05714891) | NSCLC | Recruiting | |
NCT02906943 | Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (NCT02906943) | Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gynecological Cancer, Genitourinary Cancer, Pancreatobiliary Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Rare Cancer, Unknown Primary Cancer | Recruiting | hanzhang@ohri.ca, kchristink@toh.ca |
NCT04335292 | Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (NCT04335292) | Non-Small Cell Lung Cancer | Recruiting | |
NCT05184712 | Phase 3 Clinical Study of AK112 for NSCLC Patients (NCT05184712) | Non-Squamous Non-small Cell Lung Cancer | Recruiting | |
NCT04093167 | Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC (NCT04093167) | Non-Small Cell Lung Cancer | Recruiting | |
NCT04871412 | The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage II (NCT04871412) | Lung Cancer, Gastric Cancer, Esophageal Cancer | Recruiting | afazekas@toh.ca |